PharmaMar shares soar after drug study suggests efficacy against Omicron
Shares in PharmaMar jumped almost 20% on Tuesday after the Spanish drugmaker said lab trials suggested its Plitidepsin drug was effective against the main COVID-19 variants, including the highly contagious Omicron. Results from in-vitro tests published in the Life Science Alliance journal showed that Plitidepsin, also known as Aplidin, had a potent antiviral effect in all variants and decreased the viral load detected in animal lung tissue by 99%, the company said. The same paper also included previously published positive effects in Phase I and II clinical trials carried out on patients who were hospitalised with COVID-19.
Reuters - January 11, 2022View the full story here: https://www.reuters.com/markets/europe/spains-pharmamar-says-potential-covid-19-treatment-shows-efficacy-against-2022-01-11/